Clinical Trial Update: Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating neoadjuvant therapy with abiraterone plus androgen deprivation therapy for high-risk prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Androgen deprivation therapy (Androgen deprivation therapy)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Prostate Cancer | Phase 2 | Status: UNKNOWN